Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
Abstract
Immune checkpoint inhibitors (ICIs) to date have demonstrated limited activity in advanced ovarian cancer (OC). Folate receptor alpha (FRα) is overexpressed in the majority of OCs and presents an attractive target for a combination immunotherapy to potentially overcome resistance to ICI in OCs. The current study sought to examine clinical and immunologic responses to TPIV200, a multiepitope FRα vaccine administered with programmed death ligand 1 (PD-L1) inhibitor durvalumab in patients with advanced platinum-resistant OC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2020
- Source ID
- 10.1136/jitc-2020-000829
Entities
People
- Alexia E. Iasonos
- Aliya Holland
- Autumn S Mcdonnell
- Carol Aghajanian
- Courtney L. Erskine
- Dmitriy Zamarin
- Jacqueline M Gallagher
- Jason A. Konner
- Jean M Torrisi
- Keith L Knutson
- Lewis F Chesebrough
- Mathew S Block
- Qin Zhou
- Rachel N. Grisham
- Roisin E. O'Cearbhaill
- Sven Walderich
- Taha Merghoub
- Travis J. Hollmann
- Yanyun Li
Organizations
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- Ovarian Cancer Research Alliance